PROTEASOME DEPENDENT ACTIN REMODELING FACILITATES ANTIGEN EXTRACTION AT THE IMMUNE SYNAPSE OF B CELLS




Rosiglitazone and trametinib exhibit potent anti-tumor activity in a mouse model of muscle invasive bladder cancer

Abstract Muscle invasive bladder cancers (BCs) can be divided into 2 major subgroups-basal/squamous (BASQ) tumors and luminal tumors.Since Pparg has low or undetectable expression in BASQ tumors, we tested the effects Siemens iQ500 MB535A0S0B Double Built In Electric Oven of rosiglitazone, Pparg agonist, in a mouse model of BASQ BC.We find that ros

read more